{"nctId":"NCT00150618","briefTitle":"Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17","startDateStruct":{"date":"2004-03-30","type":"ACTUAL"},"conditions":["Attention Deficit Disorder With Hyperactivity"],"count":324,"armGroups":[{"label":"SPD503 (Guanfacine HCl) (1 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: SPD503 (1 mg)"]},{"label":"SPD503 (2 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: SPD503 (2 mg)"]},{"label":"SPD503 (3 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: SPD503 (3 mg)"]},{"label":"SPD503 (4 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: SPD503 (4 mg)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SPD503 (1 mg)","otherNames":["Guanfacine hydrochloride"]},{"name":"SPD503 (2 mg)","otherNames":[]},{"name":"SPD503 (3 mg)","otherNames":[]},{"name":"SPD503 (4 mg)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a primary diagnosis of ADHD\n* Females of childbearing potential must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test\n* Male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements\n\nExclusion Criteria:\n\n* Subject has a current, uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as severe comorbid Axis II disorders or severe Axis I disorders\n* Subject weighs less than 55 lbs or is morbidly overweight with a BMI =\\> 35\n* Subject has a history of seizure during the last 2 years or a serious tic disorder, including Tourette's Disorder\n* Subject is pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Score at 6 Weeks","description":"Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.44","spread":"1.69"},{"groupId":"OG001","value":"-18.09","spread":"1.60"},{"groupId":"OG002","value":"-20.00","spread":"1.64"},{"groupId":"OG003","value":"-20.57","spread":"1.60"},{"groupId":"OG004","value":"-12.69","spread":"1.60"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) Score at 6 Weeks","description":"The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.50","spread":"2.36"},{"groupId":"OG001","value":"-14.96","spread":"2.29"},{"groupId":"OG002","value":"-17.94","spread":"2.48"},{"groupId":"OG003","value":"-15.93","spread":"2.34"},{"groupId":"OG004","value":"-8.41","spread":"2.34"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Clinical Global Impression-Improvement (CGI-I)","description":"Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"33","spread":null},{"groupId":"OG003","value":"35","spread":null},{"groupId":"OG004","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Parent Global Assessment (PGA)","description":"Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"30","spread":null},{"groupId":"OG004","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF50) Score at 6 Weeks","description":"The Child Health Questionnaire-Parent Form (CHQ-PF50) was developed to measure the physical and psychosocial well-being of children aged 5 years of age and older. Total scoring ranges from 0-100. Increases in scores represent improved well-being in subjects as assessed by their parents.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.87"},{"groupId":"OG001","value":"0.35","spread":"0.89"},{"groupId":"OG002","value":"-0.91","spread":"0.99"},{"groupId":"OG003","value":"-2.44","spread":"0.95"},{"groupId":"OG004","value":"-0.01","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.61","spread":"1.41"},{"groupId":"OG001","value":"7.47","spread":"1.44"},{"groupId":"OG002","value":"9.07","spread":"1.61"},{"groupId":"OG003","value":"9.43","spread":"1.53"},{"groupId":"OG004","value":"6.34","spread":"1.49"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":61},"commonTop":["Somnolence","Headache","Fatigue","Upper abdominal pain","Dizziness"]}}}